亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study

作者
Massimo Terzolo,Martin Faßnacht,Paola Perotti,Rossella Libé,Darko Kaštelan,André Lacroix,Wiebke Arlt,Harm R. Haak,Paola Loli,Bénédicte Decoudier,Hélène Lasolle,Marcus Quinkler,Magalie Haissaguerre,Olivier Chabre,Philippe Caron,Antonio Stigliano,Roberta Giordano,Maria Chiara Zatelli,Irina Bancos,Maria Candida Barisson Villares Fragoso
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:11 (10): 720-730 被引量:82
标识
DOI:10.1016/s2213-8587(23)00193-6
摘要

BACKGROUND: Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the efficacy and safety of adjuvant mitotane compared with surveillance alone following complete tumour resection in patients with adrenocortical carcinoma considered to be at low to intermediate risk of recurrence. METHODS: ADIUVO was a multicentre, open-label, parallel, randomised, phase 3 trial done in 23 centres across seven countries. Patients aged 18 years or older with adrenocortical carcinoma and low to intermediate risk of recurrence (R0, stage I-III, and Ki67 ≤10%) were randomly assigned to adjuvant oral mitotane two or three times daily (the dose was adjusted by the local investigator with the target of reaching and maintaining plasma mitotane concentrations of 14-20 mg/L) for 2 years or surveillance alone. All consecutive patients at 14 study centres fulfilling the eligibility criteria of the ADIUVO trial who refused randomisation and agreed on data collection via the European Network for the Study of Adrenal Tumors adrenocortical carcinoma registry were included prospectively in the ADIUVO Observational study. The primary endpoint was recurrence-free survival, defined as the time from randomisation to the first radiological evidence of recurrence or death from any cause (whichever occurred first), assessed in all randomly assigned patients by intention to treat. Overall survival, defined as time from the date of randomisation to the date of death from any cause, was a secondary endpoint analysed by intention to treat in all randomly assigned patients. Safety was assessed in all patients who adhered to the assigned regimen, which was defined by taking at least one tablet of mitotane in the mitotane group and no mitotane at all in the surveillance group. The ADIUVO trial is registered with ClinicalTrials.gov, NCT00777244, and is now complete. FINDINGS: Between Oct 23, 2008, and Dec 27, 2018, 45 patients were randomly assigned to mitotane and 46 to surveillance alone. Because the study was discontinued prematurely, 5-year recurrence-free and overall survival are reported instead of recurrence-free and overall survival as defined in the protocol. 5-year recurrence-free survival was 79% (95% CI 67-94) in the mitotane group and 75% (63-90) in the surveillance group (hazard ratio 0·74 [95% CI 0·30-1·85]). Two people in the mitotane group and five people in the surveillance group died, and 5-year overall survival was not significantly different (95% [95% CI 89-100] in the mitotane group and 86% [74-100] in the surveillance group). All 42 patients who received mitotane had adverse events, and eight (19%) discontinued treatment. There were no grade 4 adverse events or treatment-related deaths. INTERPRETATION: Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment. FUNDING: AIFA, ENSAT Cancer Health F2-2010-259735 programme, Deutsche Forschungsgemeinschaft, Cancer Research UK, and the French Ministry of Health.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
16秒前
朝与暮完成签到,获得积分10
18秒前
27秒前
34秒前
34秒前
顾矜的应助被雪白的听寒采纳,获得10
40秒前
40秒前
may发布了新的文献求助10
41秒前
深情安青的应助被昏睡的映阳采纳,获得10
51秒前
1分钟前
Nobodyet发布了新的文献求助10
1分钟前
迷人白桃完成签到,获得积分10
1分钟前
科研通AI2S的应助被小邹采纳,获得10
1分钟前
Wd完成签到,获得积分10
1分钟前
1分钟前
1分钟前
YUAN完成签到,获得积分10
1分钟前
SunJay完成签到 ,获得积分10
1分钟前
文艺夜白完成签到,获得积分10
1分钟前
程生完成签到,获得积分10
1分钟前
小貉完成签到,获得积分10
1分钟前
2分钟前
小邹发布了新的文献求助10
2分钟前
fpy完成签到,获得积分10
2分钟前
wx完成签到,获得积分10
2分钟前
清爽老九发布了新的文献求助10
2分钟前
2分钟前
单纯寄云完成签到,获得积分10
2分钟前
澹青云完成签到 ,获得积分10
2分钟前
清爽老九完成签到,获得积分0
2分钟前
Nobodyet完成签到,获得积分10
2分钟前
江蹇完成签到,获得积分10
2分钟前
深情安青的应助被小邹采纳,获得10
2分钟前
1874发布了新的文献求助100
2分钟前
受不了12345完成签到,获得积分10
2分钟前
2分钟前
petrichor发布了新的文献求助10
3分钟前
3分钟前
大猩猩发布了新的文献求助30
3分钟前
之桃完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190113
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852162
捐赠科研通 7788317
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559990
邀请新用户注册赠送积分活动 2482862